New era looming MCC treatment
from Dermatology Times
Based on results from phase 2 clinical trials investigating immune checkpoint inhibitor, treatment for Merkel cell carcinoma may be on the brink of a paradigm change, said Dr. Isaac Brownell at the 16th World Congress on Cancers of the Skin in Vienna, Austria. Avelumab, an investigational anti-programmed death ligand-1 (anti-PD-L1) monoclonal antibody, was found to well-tolerated and effective in patients with chemotherapy-resistant metastatic MCC, providing rapid and durable responses. Similarly, the PD-1 inhibitor pembrolizumab (Keytruda, Merck) demonstrated therapeutic benefit as a first-line treatment for metastatic MCC.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063